Home » Stocks » Jupiter Wellness

Jupiter Wellness, Inc. (JUPW)

Jupiter Wellness will go public soon. The estimated IPO date is October 21, 2020.
Stock Price: $7.50
Confirmed IPO price

Stock Price Chart

Key Info

Market Cap 59.20M
Revenue (ttm) 580,518
Net Income (ttm) -1.70M
Shares Out 7.89M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 59.20M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.89M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.22
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield -2.87%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 101.97
PB Ratio n/a
Revenue 580,518
Operating Income n/a
Net Income -1.70M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin -292.51%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in USD.

Financial Overview

Year20192018
Revenue6,4550
Net Income / Loss-925,462-59,734
Numbers in USD.

Company Profile

Company Details

Full Name Jupiter Wellness, Inc.
Country United States
Employees 5
CEO Brian S. John

Stock Information

Ticker Symbol JUPW
Stock Exchange NASDAQ
Unique Identifier NASDAQ: JUPW
IPO Date October 21, 2020

Description

Jupiter Wellness is a cutting-edge wellness hemp-derived cannabidiol, or CBD, consumer product development company. We are in the early stage of manufacturing, distributing, and marketing a diverse line of consumer products infused with CBD. We have a proprietary, trademarked line of products: CaniSun, CaniSkin and CaniDermRX. Under the CaniSun brand, we are marketing three proprietary CBD-infused sun care lotion formulas containing various sun protection factors, or SPFs. Under the CaniDermRX brand, we are exploring a formulation of CBD with over-the-counter, or OTC, consumer products that have potentially therapeutic and medical applications. Specifically, we are exploring the use of such topical solutions for the treatment of eczema, dermatitis, and actinic keratosis, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores, and a prescription product for the treatment of burns. The CaniDermRX topical solution for the treatment of eczema dermatitis is the lead product candidate and will be initially tested in humans as an investigational cosmetic ingredient followed by clinical trials subject to the regulations of the United States Food and Drug Administration (“FDA”) under an investigational new drug, or IND, application. In parallel, we plan to initiate the development of other products. We originally anticipated developmental studies to be completed in the first quarter of 2020, however, these studies were delayed due to COVID-19. We are also actively seeking to acquire or license products in the OTC skin care market that can be infused with CBD and marketed under our CaniSkin and CaniDermRX brand names. There can be no assurances that we will acquire or enter into such partnership or licensing agreements.